On May 9, 2025, Integra LifeSciences Holdings Corp. held its Annual Meeting where stockholders approved an increase of 2,200,000 shares available for awards under the Equity Incentive Plan, elected directors, ratified an accounting firm, and approved executive compensation. Additionally, Dr. Stuart M. Essig will transition to a non-executive role effective July 1, 2025, with no disagreements reported.